Handout: Best of ASCO Bangkok 2021 (Day 1: Friday 6 August 2021) | |||
| Time | Abstract ID | Title | Presenter |
000 | Sample | Mr. …………. | |
| 8.00-9.00 | Trainee session (Thai language) | Changing Paradigms in the Treatment of Early-Stage Non–Small Cell Lung Cancer | Kunlatida Maneenil, M.D, Chonnipa Nantavithya, M.D, (RT) Assist Prof Punnarerk Thongcharoen ( CVT) |
| Melanoma session | |||
| 9.10-9.20 | 9503
| Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047). | Jomjt Chantharasmee, M.D. |
| 9.20-9.30 | 9502
| Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. | Jomjt Chantharasmee, M.D. |
| supportive and survivor care | |||
| 11.40-11.50 | 12003
| Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. | Yodsawat Runglodvatana, M.D. |
| 11.50-12.00 | 12010
| The effects of geriatric assessment on oncologist-patient communication regarding functional status and physical performance in older adults with cancer: A secondary analysis of a 541-subject nationwide URCC NCORP (NCI Community Oncology Research Program) cluster randomized trial. | Yodsawat Runglodvatana, M.D. |
| 12.15-13.00 | symposium by Zuellig Pharma (Eli Lilly): Optimizing CDK 4/6 inhibitors treatment outcomes in HER2-/HR+ Metastatic Breast Cancer | Dr. Shaheenah Dawood (UAE) | |
| Metastatic breast cancer session | |||
| 13.20-13.30 | 1003
| Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. | NAPA PARINYANITIKUL, M.D. |
| 13.30-13.40 | 1002
| Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. | NAPA PARINYANITIKUL, M.D. |
| Non-colorectal GI cancer | |||
| 13.55-14.05 | LBA4001
| Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. | TEERAPAT UNGTRAKUL, M.D. |
| 14.05-14.15 | 4007
| Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study). | TEERAPAT UNGTRAKUL, M.D. |
| 14.15-14.25 | 4006
| Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY) | TEERAPAT UNGTRAKUL, M.D. |
| 15.00-15.45 | Symposium by Eisai: REFLECT a State-of-the-Art Treatment Strategy in Intermediate and Advanced HCC | Asst. Prof. Suebpong Tanasanvimon | |
| Colorectal cancer session | |||
| 15.50-16.00 | 3504
| Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. | Assoc.Prof.KRITTIYA KORPHAISARN |
| 16.00-16.10 | 3505
| Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). | Assoc.Prof. KRITTIYA KORPHAISARN |
| 16.30-17.15 | Symposium by Pfizer: The Next Line: New Therapeutic approach for ALK NSCLC patient” | Assoc. Prof. Thanyanun Reungwetwattana | |
Handout: Best of ASCO Bangkok 2021 (Day 2: Saturday 7 August 2021) | |||
| Time | Abstract ID | Title | Presenter |
| 8:00-8:45 | Symposium by MSD: On the Horizon : Sustained survivability with IO combinations in advanced NSCLC. | Stephen V. Liu, MD. | |
| 8.45-9.45 | Trainee session (Thai language) | Next Steps: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era | Dr.Pongwut Danchivijitr, (Med Oncologist) Assoc. Prof Kittinut Kijvikai, (Urologist) Petch Alisanasnt, M.D. (RT) |
| 10.05-10.50 | Symposium by BMS: First Line Dual IO’ The Key to Moving Forward in Lung Cancer Treatments | TBA | |
| Genitourinary cancer session | |||
| 10.50-11.00 | LBA5
| Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study. | NATTAYA POOVORAWAN, M.D. |
| 11.00-11.10 | 4500
| Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC). | NATTAYA POOVORAWAN, M.D. |
| 11.10-11.20 | 5000
| A phase 3 trial with a 2×2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. | JARIN CHINDAPRASIRT, M.D. |
| 11.20-11.30 | LBA4
| Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). | JARIN CHINDAPRASIRT, M.D. |
| 11.55-12.40 | Symposium by Roche: The Changing Treatment Paradigm in Unresectable HCC : Incorporating Evidence into Clinical Practice. | Assoc.Prof.CHAIYUT CHAROENTUM Assoc.Prof.EKAPHOP SIRACHAINAN | |
| Head and neck cancer session | |||
| 13.00-13.10 | LBA2
| JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). | Assist.Prof.NUTTAPONG NGAMPHAIBOON |
| 13.10-13.20 | 6000
| Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial. | Assist.Prof.NUTTAPONG NGAMPHAIBOON |
| 13.20-13.30 | 6003
| Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial. | Kunlatida Maneenil, M.D |
| 13.30-13.40 | 6001
| Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial. | Kunlatida Maneenil, M.D |
| 14.25-15.10 | Symposium by Takeda: Promising first line treatment option for patients with ALK-positive NSCLC | Dr. Pongwut Danchaivijitr | |
| Lung cancer session | |||
| 15.15-15.25 | 8500
| IMpower010: Primary results of a phase III global study of atezolizumab vs. best supportive care after adjuvant chemotherapy in resected Stage IB-IIIA non-small cell lung cancer (NSCLC). | Siriwimon Saichamchan, M.D. |
| 15.25-15.35 | 9006
| Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. | Siriwimon Saichamchan, M.D. |
| 15.35-15.45 | 9000
| First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. | PIYADA SITTHIDEATPHAIBOON, M.D. |
| 15.45-15.55 | 9001
| Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. | PIYADA SITTHIDEATPHAIBOON, M.D. |
Menu